Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Polycystic Ovarian Syndrome
IRCT20220822055771N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in polycystic ovary syndrome (PCOS), sponsored by Shahrekord University of Medical Sciences. Started Nov 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20220822055771N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220822055771N1.